Cue Biopharma Downgraded to Sell, Following Massive $24.14 Per Share Loss

Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from hold to sell on Sunday. This action contributes to a consensus sell rating for the company.

The company recently reported a quarterly loss of $24.14 per share. This result missed consensus estimates, though revenue surpassed expectations.

The downgrade follows a period of stock price volatility. Shares have already fallen from their 12-month high.